Infectious Disease
COVID-19 Ag Rapid Test
Detects SARS-CoV-2 antigen. colloidal-gold. Specimen: NP swab / Nasal swab.
| Target / Analyte | SARS-CoV-2 antigen |
|---|---|
| Disease / Indication | COVID-19 |
| Series | Infectious Disease |
| Method | colloidal-gold |
| Specimen | NP swab / Nasal swab |
| Test time | 10–15 min (product-specific) |
| Storage | 2–30 °C, sealed pouch with desiccant |
| Shelf life | 24 months (product-specific) |
| Regulatory | CE (IVDD 98/79/EC) |
| OEM/ODM | Available — private label & custom panel |
Direct Answer
This rapid test detects SARS-CoV-2 antigen in NP swab / Nasal swab to support COVID-19. It is a colloidal-gold screening test — a reactive result is presumptive and should be confirmed per the intended use.
Intended Use
Detection of SARS-CoV-2 antigen (nucleocapsid) from nasal/nasopharyngeal swab.
Clinical Context
Rapid antigen tests (RATs) detect active SARS-CoV-2 infection; most sensitive when viral load is high (early symptomatic phase).
Test Principle
Colloidal-gold immunochromatography (lateral flow). The device captures the target analyte (antigen or antibody) on a membrane via labeled antibodies, producing a visible test line within minutes. Qualitative or semi-quantitative, intended as a screening/triage aid — not a replacement for confirmatory laboratory testing.
Limitations
Less sensitive than RT-PCR, especially asymptomatic/low viral load; repeat testing is often recommended.
Procurement
Specimen: NP / nasal swab. Format: device, 20 T. CE-marked line.
Interpretation
| Result | Lines | Meaning |
|---|---|---|
| Positive | Test + control line | Target detected (presumptive positive) |
| Negative | Control line only | Below cut-off / not detected |
| Invalid | No control line | Repeat with a new device |
Common misconception
A negative rapid test does not always exclude infection — timing, specimen and pathogen load all matter. Follow up clinically where suspicion is high.
Sources
Screening results are presumptive, not diagnostic. Confirmatory testing follows WHO, CDC and national regulatory guidance — see screening vs confirmatory.
Technical Evidence
| Analytical performance | Sensitivity, specificity, cut-off and precision are documented per product line in the datasheet and validation report. |
|---|---|
| Average accuracy | ≥96% (overall agreement rate, manufacturer-validated). Per-product sensitivity and specificity are documented in the datasheet. |
| Clinical performance | Evaluation data (study population, reference method, agreement) available on request. |
| Cross-reactivity | Documented per analyte — see limitations above. |
| Documents | IFU · Datasheet · Certificate · Declaration of Conformity — request below. |
Buyer Information
| MOQ | Product-dependent — low MOQ available on specialty assays |
|---|---|
| OEM / private label | Custom branding, cut-off, panel and packaging |
| Samples | Available for evaluation — request via RFQ |
| Lead time | On request |
| Documents | IFU · Datasheet · COA · Validation report · CE files · Registration support |
Related knowledge
Documentation & quotation — datasheet, IFU, certificate, MOQ and OEM/ODM options on request.
Request IFU / Spec Sheet Request Datasheet Request Certificate
Last reviewed: 2026-09-12